@AASLDtweets great #livermtg16 ends. Thks to @AASLDPresident & world class staff! Great to see social media emphasis & footprint!

@AASLDtweets Debrief: "can choose a treatment regimen that cures everyone. Rest is between you & the insurance company" #livermtg16

@AASLDtweets the only remaining unmet need in #HCV today is improved access. Public policy needs to catch up to science. #livermtg16

@AASLDtweets Prof. Foster: "the final nail in the #HCV coffin" #livermtg16

@AASLDtweets Prof. Foster: 8 wks of SOF/VEL/VOX cures 96% GT3 cirrhotics (30%TE) 2 relapsers had TE Y93X. 15% diarrhea #livermtg16

@AASLDtweets Dr. Cholankeril: re-transplantation for #HCV declined 95% between 2005 & 2014. #DAAs making this a non issue #LiverMtg16

@AASLDtweets Dr. Donato: #fibroscan predicts fibrosis stages well in #HCV DAA treated pts before & after transplant #livermtg16

@AASLDtweets there may not be any questions left in #HCV but plenty left in #HEV #Livermtg16

@AASLDtweets About 1/3 #HEV transplant pts spontaneously clear. Lower immunosuppression when infection detected #LiverMtg16

@AASLDtweets one has to wonder what the new acceptable "low" for #HCV SVR12 is. Most failures non virological anyway #livermtg16

@AASLDtweets Prof. Zeuzem in response to lack of audience questions: "There are no questions left in #HCV"
#livermtg16

@AASLDtweets Prof. Zeuzem: 8 wk GLE/PIB cures 99-100% GT1 non cirrhotic mono/co-infected #HCV pts including few SOF-exp #LiverMtg16

@AASLDtweets Dr. Jacobson: SOF/VEL/VOX 8 wks non inferior to SOF/VEL 12 wks. More relapses in GT1a and mild diarrhea in 18% #livermtg16

@AASLDtweets when it comes to #HCV SVR12, 98% is the new 95%...#livermtg16

@AASLDtweets Dr. Gane: Glec/Pib cures 98% renally impaired #HCV Pts. No virological failures. Good safety #livermtg16

@AASLDtweets PD-1 immune checkpoint inhibitors poised to be game changers in #HCC. Ph2/3 trials of #keytruda and #opdivo #livermtg16

@AASLDtweets Dr. Sangro: early durable Response (OS 14-15 mos) for #nivolumab in #HCC including #nexavar failures #LiverMtg16

@AASLDtweets Dr. Jones: MBX-8025 drops alk phos in #PBC UDCA non responders. No itching. ALT rise seen. Lower dose? #livermtg16 @PBCers

@AASLDtweets #livermtg16 with a Christmas motif? #LiverSnaps

@AASLDtweets No #livermtg16 in #Boston is complete without worshiping at the altar of the high temple of shellfish #LiverSnaps

@AASLDtweets highlights of closing day of #livermtg16 incl. data for $ABBV Glec/Pib in renal pts and $GLD Sof/Vel/Vox in DAA-Naive GT1-6

@AASLDtweets incoming #AASLD prez Anna Lok @UMHealthSystem will deliver her vision for #HBV elimination on closing day of #livermtg16

@AASLDtweets Dr. Feld: Variant in RAV refers to whole virus. Substitution in RAS refers to individual genetic change from WT. #livermtg16

@AASLDtweets Dr. Grebely: about 10% of Australians w #HCV will be cured this year. "Proud to be Australian" #LiverMtg16

@AASLDtweets Dr. Grebely: Risk of #HCV reinfection 6%/year or 4 /100 PY. #harmreduction critical. May get to rx as prevention #livermtg16

@AASLDtweets Dr. Grebely: both clinical trial and real world data in recent drug users are very good >95% SVR12 #livermtg16

@AASLDtweets Dr. Grebely: #HCV Treatment of #PWID may prevent infection by shrinking the pool of exposures #harmreduction #LiverMtg16

@AASLDtweets Dr. Roth: nephrologists have to be involved in the decision and timing of #HCV therapy @ASNKidney @nkf #livermtg16

@AASLDtweets waitlisted pts eligible for HCV+ organs get a kidney within weeks in Miami. Average national wait time 6 years #LiverMtg16

@AASLDtweets Dr. Roth: minority of #HCV patients with kidney disease have been treated. Evidence they do well with DAAs #LiverMtg16